DASGIB: Central Nervous System Infections in Denmark

Sponsor
Aalborg University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT03418441
Collaborator
Danish Study Group of Infections of the Brain (Other)
1,900
8
120
237.5
2

Study Details

Study Description

Brief Summary

The Danish Study Group of Infections of the Brain is a collaboration between all departments of infectious diseases in Denmark. The investigators aim to monitor epidemiological trends in central nervous system (CNS) infections by a prospective registration of clinical characteristics and outcome of all adult (>17 years of age) patients with community-acquired CNS infections diagnosed and/or treated at departments of infectious diseases in Denmark since 1st of January 2015.

Detailed Description

The investigators include data on diagnosis at admission, symptoms and signs on admission, character and timing of diagnostic work-up and treatment and outcome assessed by the Glasgow Outcome Score (GOS).

Diagnostic work-up and treatment is left at the discretion of the local physician and therefore not standardised

In general any symptoms/deficits should only be listed if they are 'new' to the patient, e.g. a known palsy of the facial nerve should not be listed as a new relevant finding at admission. On the other hand, worsening of a known neurological deficit should be listed under signs in the given instrument (bacterial meningitis, encephalitis, neuroborreliosis etc). Likewise, for outcome only changes in pre-morbid conditions should be listed including place of residence, functional status, neurological deficits etc.

Time of admission is obtained in prioritized order from the ambulance charts or notifications of arrival by secretaries or nurses in the emergency departments. Timing of lumbar puncture and cranial imaging is extracted from the electronic records at the departments of biochemistry or radiology while timing of antibiotic therapy for meningitis is identified in electronic medication systems. Time to lumbar puncture, cranial imaging and antibiotic therapy is calculated as time from arrival at hospital to each of the above events.

Quality control of case enrollment is ensured by ad hoc case-to-case discussions and at study group meetings 2-3 times a year

To ensure completeness of reported CNS infections annual searches of selected International Classification of Diseases version 10 (ICD-10) codes are performed in local administrative databases at each department:

A17 A32.1 A32.7 A39.0 A52.1-52.3 A69.2 (neuroborreliosis) A83 A84 A85 A87 A89 B00.3-00.4 B01.0-01.1 B02.0-02.0 B582 B451 B375 G00 G01 G02 G03 G04 G05 G06 G07

Study Design

Study Type:
Observational
Anticipated Enrollment :
1900 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Danish Study Group of Infections of the Brain: A Nationwide Prospective Observational Cohort Study of All Central Nervous System Infections in Adults at Departments of Infectious Diseases in Denmark
Actual Study Start Date :
Jan 1, 2015
Anticipated Primary Completion Date :
Jan 1, 2025
Anticipated Study Completion Date :
Jan 1, 2025

Outcome Measures

Primary Outcome Measures

  1. Incidence [One year]

    Incidence of CNS infections in the adult population (>17 years of age) in Denmark.

Secondary Outcome Measures

  1. Glasgow Outcome Scale score [One month after end of treatment]

    A five tier assessment of functional status, 1=Death, 2=vegetative state, 3=dependency on others for daily activities, 4=some sequelae but able to live independently, 5= No or only minor sequelae

  2. Glasgow Outcome Scale score for viral meningitis [30 days]

    A five tier assessment of functional status, 1=Death, 2=vegetative state, 3=dependency on others for daily activities, 4=some sequelae but able to live independently, 5= No or only minor sequelae

  3. Glasgow Outcome Scale score for bacterial meningitis [30 days]

    A five tier assessment of functional status, 1=Death, 2=vegetative state, 3=dependency on others for daily activities, 4=some sequelae but able to live independently, 5= No or only minor sequelae

  4. Glasgow Outcome Scale score for encephalitis [30 days]

    A five tier assessment of functional status, 1=Death, 2=vegetative state, 3=dependency on others for daily activities, 4=some sequelae but able to live independently, 5= No or only minor sequelae

  5. Glasgow Outcome Scale score for neurosyphilis [2 weeks]

    A five tier assessment of functional status, 1=Death, 2=vegetative state, 3=dependency on others for daily activities, 4=some sequelae but able to live independently, 5= No or only minor sequelae

  6. Glasgow Outcome Scale score for neuroborreliosis [2 weeks]

    A five tier assessment of functional status, 1=Death, 2=vegetative state, 3=dependency on others for daily activities, 4=some sequelae but able to live independently, 5= No or only minor sequelae

  7. Glasgow Outcome Scale score for brain abscess [8 weeks]

    A five tier assessment of functional status, 1=Death, 2=vegetative state, 3=dependency on others for daily activities, 4=some sequelae but able to live independently, 5= No or only minor sequelae

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Definitions of central nervous system infections:

For all cases with unproven aetiologies no alternative diagnosis than CNS infection is thought more likely after completed multidisciplinary diagnostic work-up.

Viral meningitis inclusion criteria

  • All patients have to have a clinical presentation consistent with non-bacterial meningitis (e.g. headache, neck stiffness, photo- or phonophobia, fever)

and

Cerebrospinal fluid leukocytes>10 cells/ml

Patients with viral meningitis with undetermined pathogen have to have:
  • CSF leukocytes> 10/mL and no other more probable diagnosis assessed by the local investigator.

In case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.

Bacterial meningitis inclusion criteria - All patients have to have a clinical presentation consistent with bacterial meningitis (e.g. headache, neck stiffness, fever, altered mental status)

and

Proven bacterial aetiology (CSF or blood culture/DNA based technology or antigen tests)

Patients with bacterial meningitis in whom the bacteria cannot not be cultured or identified by DNA-based technologies have to have:

  • CSF leukocytes> 10/mL and no other more probable diagnosis assessed by the local investigator.

In case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.

Encephalitis inclusion criteria - All patients have to have a clinical presentation consistent with encephalitis (e.g. headache, fever, focal neurological deficit, altered mental status >24 hours) as defined by the International Encephalitis Consortium (Venkatesan A et al., Clin Infect Dis 2013; doi:10.1093/cid/cit458.).

Encephalitis exclusion criteria

  • We exclude cases of proven or suspected autoimmune encephalitis.

Primary brain abscess inclusion criteria

  • All patient have a clinical presentation consistent with brain abscess (e.g. headache, focal neurological deficit, mass lesion on cranial imaging)

and

  • Proven microbiological aetiology by culture/DNA-based technology from pus from brain abscess or blood or CSF

or

  • Aspiration of pus from the brain abscess

or

  • Response to antimicrobial treatment

or

  • Tumour ruled out

or

  • Tumour thought less probable than abscess on MRI using diffusion weighted imaging (DWI) and apparent diffusion coefficient (ADC) sequences.

Lyme neuroborreliosis inclusion criteria

  • A clinical presentation consistent with neuroborreliosis (e.g. radiculopathy)

and

  • CSF pleocytosis>10 leukocytes/mL

and

  • Positive intrathecal B.burgdorferi antibody production index.

Neurosyphilis inclusion criteria - A clinical presentation consistent with neurosyphilis (e.g. 'encephalitis-like symptoms', dementia, ocular or otogenic syphilis)

and either

  • Positive syphilis serology in serum combined with CSF leukocytes>10/mL

or

  • CSF syphilis antibodies.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Infectious Diseases, Aalborg University Hospital Aalborg Denmark 9000
2 Department of Infectious Diseases, Aarhus University Hospital Skejby Aarhus Denmark 8000
3 Department of Infectious Diseases, Rigshospitalet Copenhagen Denmark 2100
4 Herlev-Gentofte Hospital Copenhagen Denmark
5 Department of Pulmonary and Infectious Diseases, Nordsjællands Hospital Hillerød Hillerød Denmark 3400
6 Department of Infectious Diseases, Hvidovre Hospital Hvidovre Denmark 2650
7 Department of Infectious Diseases, Odense University Hospital Odense Denmark 5100
8 Department of Pulmonary and Infectious Diseases, Sjællands University Hospital Roskilde Roskilde Denmark 4000

Sponsors and Collaborators

  • Aalborg University Hospital
  • Danish Study Group of Infections of the Brain

Investigators

  • Study Chair: Henrik Nielsen, Professor, Aalborg University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jacob Bodilsen, Doctor, Aalborg University Hospital
ClinicalTrials.gov Identifier:
NCT03418441
Other Study ID Numbers:
  • DASGIB
First Posted:
Feb 1, 2018
Last Update Posted:
Jul 21, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jacob Bodilsen, Doctor, Aalborg University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 21, 2021